This notification is intended for our Mercy Care Advantage Hospital network.
On October 24, 2019 an article was published in Medicare Learning Network (MLN) Matters regarding the billing for Chimeric Antigen Receptor (CAR) T-Cell therapy. This article conveys information on the National Coverage Determination (NCD) requiring coverage of Chimeric Antigen Receptor (CAR) T-cell therapy for cancer. For more information on the National Coverage Determination, please see the
decision memorandum
.
These new billing requirements were implemented and went into effect on August 17, 2019.
The Centers for Medicare & Medicaid Services (CMS) provided this information for hospitals providing CAR T-cell therapy to beneficiaries enrolled in Mercy Care Advantage and other Medicare Advantage (MA) plans. Please make sure your billing staff is aware of these instructions if you are billing for this service.
As always, don't hesitate to contact your
Mercy Care
Provider Relations Representative with any questions or comments. You can find this notice and all other provider notices on our
Mercy Care
website.
Thanks for your attention to this important matter.
